Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (RMN) systems for use in hospital’s interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease in the United States and internationally. More Details
Flawless balance sheet with limited growth.
Share Price & News
How has Stereotaxis's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: STXS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: STXS's weekly volatility (9%) has been stable over the past year.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: STXS underperformed the US Medical Equipment industry which returned 20.5% over the past year.
Return vs Market: STXS underperformed the US Market which returned 21% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Stereotaxis's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StInvestors Who Bought Stereotaxis (NYSEMKT:STXS) Shares Five Years Ago Are Now Up 597%
1 month ago | Simply Wall StWhat Kind Of Investors Own Most Of Stereotaxis, Inc. (NYSEMKT:STXS)?
3 months ago | Simply Wall StHealth Check: How Prudently Does Stereotaxis (NYSEMKT:STXS) Use Debt?
Is Stereotaxis undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate STXS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate STXS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: STXS is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: STXS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate STXS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: STXS is overvalued based on its PB Ratio (9.9x) compared to the US Medical Equipment industry average (5x).
How is Stereotaxis forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: STXS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: STXS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: STXS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: STXS's revenue (30.2% per year) is forecast to grow faster than the US market (10.2% per year).
High Growth Revenue: STXS's revenue (30.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if STXS's Return on Equity is forecast to be high in 3 years time
How has Stereotaxis performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: STXS is currently unprofitable.
Growing Profit Margin: STXS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: STXS is unprofitable, but has reduced losses over the past 5 years at a rate of 10.1% per year.
Accelerating Growth: Unable to compare STXS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: STXS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.3%).
Return on Equity
High ROE: STXS has a negative Return on Equity (-16.13%), as it is currently unprofitable.
How is Stereotaxis's financial position?
Financial Position Analysis
Short Term Liabilities: STXS's short term assets ($53.9M) exceed its short term liabilities ($13.4M).
Long Term Liabilities: STXS's short term assets ($53.9M) exceed its long term liabilities ($3.1M).
Debt to Equity History and Analysis
Debt Level: STXS's debt to equity ratio (5.3%) is considered satisfactory.
Reducing Debt: STXS had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: STXS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: STXS has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 12.2% each year
What is Stereotaxis's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate STXS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate STXS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if STXS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if STXS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of STXS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
David Fischel (33 yo)
Mr. David Leo Fischel, CPA, CFA, CAIA, MBA, has been the Chairman and Chief Executive Officer of Stereotaxis, Inc. since February 3, 2017. Mr. Fischel is a Principal and primary portfolio manager for medic...
|CEO & Chairman||3.92yrs||US$240.30k||0.029% |
|Independent Director||4.33yrs||US$240.30k||0.48% |
|Independent Director||4.33yrs||US$240.30k||8.94% |
|Independent Director||15.67yrs||US$240.30k||0.17% |
|Lead Independent Director||5.92yrs||US$240.30k||0.44% |
|Independent Director||2.58yrs||US$240.30k||no data|
Experienced Board: STXS's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.5%.
Stereotaxis, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Stereotaxis, Inc.
- Ticker: STXS
- Exchange: AMEX
- Founded: 1990
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$323.418m
- Shares outstanding: 69.03m
- Website: https://www.stereotaxis.com
Number of Employees
- Stereotaxis, Inc.
- 4320 Forest Park Avenue
- Suite 100
- Saint Louis
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|STXS||AMEX (NYSE MKT LLC)||Yes||Common Shares||US||USD||Aug 2004|
Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (RMN) systems for use in hospital’s interventional surgical suite to enhance the treatment of arrhythmias and coronary arter...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/16 00:09|
|End of Day Share Price||2021/01/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.